Cytek Biosciences (CTKB) Depreciation & Amortization (CF) (2020 - 2026)

Cytek Biosciences' Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 0.53% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.6 million (up 2.45% YoY) and the FY2025 annual result came in at $7.6 million, up 5.09% from the prior year.
• Depreciation & Amortization (CF) was $1.9 million for Q1 2026 at Cytek Biosciences, down from $1.9 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $1.9 million in Q3 2025 and bottomed at $72000.0 in Q3 2022.
• A 5-year average of $1.5 million and a median of $1.8 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) slumped 61.9% — and 2023, when it jumped 2354.17%.
• Cytek Biosciences' Depreciation & Amortization (CF) stood at $761000.0 in 2022, then jumped by 114.32% to $1.6 million in 2023, then gained by 13.67% to $1.9 million in 2024, then grew by 2.27% to $1.9 million in 2025, then dropped by 1.64% to $1.9 million in 2026.
• Business Quant data shows CTKB's Depreciation & Amortization (CF) at $1.9 million in Q1 2026, $1.9 million in Q4 2025, and $1.9 million in Q3 2025.